금융 뉴스 허브
실시간 글로벌 금융 시장 뉴스 · 분석 · 인사이트
BREAKING주요 뉴스
PBOC sets USD/CNY reference rate at 6.7162 vs. 6.7180 previous
On Monday, the People’s Bank of China (PBOC) sets the USD/CNY central rate for the trading session a...
U.S. stock futures edge higher after bruising tech losses; Fed, earnings on tap
Investing.com-- U.S. stock index futures rose slightly on Sunday evening after logging deep, technol...
WTI drops to near 101.00 as Trump rules out immediate Iranian strikes
West Texas Intermediate (WTI) oil price declines after registering over 4% gains in the previous tra...
United States CFTC Gold NC Net Positions declined to $183.9K from previous $186.7K
SpaceX in focus as Morgan Stanley ponders 'zero' AI value; Musk previews new models
First Hawaiian outlines 3%-4% loan growth and 3.24%-3.25% NIM outlook while advancing TriCo deal
The world is facing its largest oil shock ever. Here is why prices are not higher.
Oil prices aren’t yet near the level economists had said would put the global economy in jeopardy of a recession.
3 Reasons We’re Fans of Natera (NTRA)
Natera has followed the market’s trajectory closely, rising in tandem with the S&P 500 over the past six months. The stock has climbed by 9.1% to $263.44 per share while the index has gained 7.9%.
Forecasting the upcoming week: Fed, BoE and BoJ decisions take center stage
The upcoming week will be dominated by monetary policy decisions from the Federal Reserve (Fed), Bank of England (BoE) and Bank of Japan (BoJ).
Are You a New Investor in 2026? Here's 1 Costly Mistake to Avoid.
It's often better to focus on minimizing blunders than to try and be exceptional.
NZD/USD Price Forecast: Tests 0.5800 as bullish momentum fades
The New Zealand Dollar gains over 0.30% against the US Dollar, poised to test key resistance levels, with the 50-day Simple Moving Average (SMA) at 0.5793, slightly below the 0.5800 figure. At the tim ...
HCA projects $77B-$79.5B 2026 revenue amid (-$1B)-(-$1.2B) exchange headwind
3 Reasons to Avoid MMI and 1 Stock to Buy Instead
Marcus & Millichap trades at $29.92 and has moved in lockstep with the market. Its shares have returned 11.5% over the last six months while the S&P 500 has gained 7.9%.
Outlook gains approval for ophthalmic bevacizumab for wet AMD
Looks like we don't need to worry about that Fort Knox Gold audit anymore
I’ve got some fantastic news.